An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibVIJ, Ravi; SIEGES, David S; WONG, Alvin F et al.British journal of haematology. 2012, Vol 158, Num 6, pp 739-748, issn 0007-1048, 10 p.Article

Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibitionHUGHES, Dennis P. M; THOMAS, Dafydd G; GIORDANO, Thomas J et al.Pediatric blood & cancer. 2006, Vol 46, Num 5, pp 614-623, issn 1545-5009, 10 p.Article

Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcomaHUGHES, Dennis P. M; THOMAS, Dafydd G; GIORDANO, Thomas J et al.Cancer research (Baltimore). 2004, Vol 64, Num 6, pp 2047-2053, issn 0008-5472, 7 p.Article

Antigen-specifictumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHCNEELEY, Yilin C; MCDONAGH, Kevin T; OVERWIJK, Willem W et al.The Prostate. 2002, Vol 53, Num 3, pp 183-191, issn 0270-4137Article

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemiaKELLY, Kevin R; SHEA, Thomas C; HUIFENG NIU et al.Investigational new drugs. 2014, Vol 32, Num 3, pp 489-499, issn 0167-6997, 11 p.Article

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesMCSWEENEY, Peter A; NASH, Richard A; HOLMBERG, Leona A et al.Blood. 2002, Vol 100, Num 5, pp 1602-1610, issn 0006-4971, 9 p.Article